Biogen Inc. (BIIB) exceeded analysts’ expectations for both earnings and revenue in the third quarter, but its shares fell after the announcement. The company raised its 2024 earnings guidance and expects operating income to grow significantly. Analyst opinions on Biogen’s future prospects are mixed, with some downgrading their ratings while others remain bullish.